Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery

Genetic Test Seen to Predict Patients Helped by ADT Use After Surgery
A genetic test, called Decipher Prostate RP, can help to identify those prostate cancer patients with a relapse after surgery who will benefit most by adding androgen deprivation therapy (ADT) to radiation therapy, a new analysis of clinical trial data shows. “Identifying which patients with recurrent disease are most likely to benefit from hormonal therapy will improve our ability to extend patient survival, while minimizing unnecessary toxicity for a large group of men with prostate cancer,” Felix Feng, MD, vice chair of radiation oncology at University of California, in San Francisco, said in a press release. The data, “Transcriptome profiling of NRG Oncology/RTOG 9601: Validation of a prognostic genomic classifier in salvage radiotherapy prostate cancer patients from a prospective randomized trial,” were presented at the 2020 American Society of Clinical Ongology (ASCO) Genitourinary Cancer Symposium, held Feb. 13–15, in San Francisco. Until recent year
Subscribe or to access all post and page content.